Karyopharm Therapeutics Stock Technical Analysis
KPTI Stock | USD 1.39 0.09 6.08% |
As of the 28th of March, Karyopharm Therapeutics secures the Risk Adjusted Performance of 0.0928, mean deviation of 6.19, and Downside Deviation of 6.27. Karyopharm Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Karyopharm Therapeutics, which can be compared to its peers in the industry. Please verify Karyopharm Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Karyopharm Therapeutics is priced some-what accurately, providing market reflects its recent price of 1.39 per share. Given that Karyopharm Therapeutics is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.
Karyopharm Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Karyopharm, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to KaryopharmKaryopharm |
Karyopharm Therapeutics Analyst Consensus
Target Price | Advice | # of Analysts | |
6.67 | Strong Buy | 7 | Odds |
Most Karyopharm analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Karyopharm stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Karyopharm Therapeutics, talking to its executives and customers, or listening to Karyopharm conference calls.
Karyopharm Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Karyopharm Therapeutics Technical Analysis
The output start index for this execution was three with a total number of output elements of fifty-eight. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Karyopharm Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Karyopharm Therapeutics Trend Analysis
Use this graph to draw trend lines for Karyopharm Therapeutics. You can use it to identify possible trend reversals for Karyopharm Therapeutics as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Karyopharm Therapeutics price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.Karyopharm Therapeutics Best Fit Change Line
The following chart estimates an ordinary least squares regression model for Karyopharm Therapeutics applied against its price change over selected period. The best fit line has a slop of 0.01 , which means Karyopharm Therapeutics will continue generating value for investors. It has 122 observation points and a regression sum of squares at 6.38, which is the sum of squared deviations for the predicted Karyopharm Therapeutics price change compared to its average price change.About Karyopharm Therapeutics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Karyopharm Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Karyopharm Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Karyopharm Therapeutics price pattern first instead of the macroeconomic environment surrounding Karyopharm Therapeutics. By analyzing Karyopharm Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Karyopharm Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Karyopharm Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
2021 | 2022 | 2023 | 2024 (projected) | Days Of Sales Outstanding | 39.14 | 109.42 | 67.39 | 52.74 | Days Of Inventory Outstanding | 440.53 | 295.75 | 202.98 | 215.76 |
Karyopharm Therapeutics March 28, 2024 Technical Indicators
Most technical analysis of Karyopharm help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Karyopharm from various momentum indicators to cycle indicators. When you analyze Karyopharm charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Risk Adjusted Performance | 0.0928 | |||
Market Risk Adjusted Performance | (1.06) | |||
Mean Deviation | 6.19 | |||
Semi Deviation | 5.36 | |||
Downside Deviation | 6.27 | |||
Coefficient Of Variation | 665.37 | |||
Standard Deviation | 8.19 | |||
Variance | 67.1 | |||
Information Ratio | 0.1339 | |||
Jensen Alpha | 1.36 | |||
Total Risk Alpha | (0.61) | |||
Sortino Ratio | 0.1751 | |||
Treynor Ratio | (1.07) | |||
Maximum Drawdown | 42.59 | |||
Value At Risk | (9.76) | |||
Potential Upside | 15.56 | |||
Downside Variance | 39.25 | |||
Semi Variance | 28.69 | |||
Expected Short fall | (8.79) | |||
Skewness | 1.05 | |||
Kurtosis | 1.8 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.25) | Revenue Per Share 1.279 | Quarterly Revenue Growth 0.005 | Return On Assets (0.27) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.